These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39006421)

  • 1. A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests.
    Warmenhoven N; Salvadó G; Janelidze S; Mattsson-Carlgren N; Bali D; Dolado AO; Kolb H; Triana-Baltzer G; Barthélemy NR; Schindler SE; Aschenbrenner AJ; Raji CA; Benzinger TLS; Morris JC; Ibanez L; Timsina J; Cruchaga C; Bateman RJ; Ashton N; Arslan B; Zetterberg H; Blennow K; Pichet Binette A; Hansson O
    medRxiv; 2024 Jul; ():. PubMed ID: 39006421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
    Warmenhoven N; Salvadó G; Janelidze S; Mattsson-Carlgren N; Bali D; Orduña Dolado A; Kolb H; Triana-Baltzer G; Barthélemy NR; Schindler SE; Aschenbrenner AJ; Raji CA; Benzinger TLS; Morris JC; Ibanez L; Timsina J; Cruchaga C; Bateman RJ; Ashton N; Arslan B; Zetterberg H; Blennow K; Pichet Binette A; Hansson O
    Brain; 2024 Oct; ():. PubMed ID: 39468767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
    Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
    Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
    Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.
    Groot C; Cicognola C; Bali D; Triana-Baltzer G; Dage JL; Pontecorvo MJ; Kolb HC; Ossenkoppele R; Janelidze S; Hansson O
    Alzheimers Res Ther; 2022 May; 14(1):67. PubMed ID: 35568889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.
    Barthélemy NR; Salvadó G; Schindler SE; He Y; Janelidze S; Collij LE; Saef B; Henson RL; Chen CD; Gordon BA; Li Y; La Joie R; Benzinger TLS; Morris JC; Mattsson-Carlgren N; Palmqvist S; Ossenkoppele R; Rabinovici GD; Stomrud E; Bateman RJ; Hansson O
    Nat Med; 2024 Apr; 30(4):1085-1095. PubMed ID: 38382645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.
    Janelidze S; Barthélemy NR; Salvadó G; Schindler SE; Palmqvist S; Mattsson-Carlgren N; Braunstein JB; Ovod V; Bollinger JG; He Y; Li Y; Raji CA; Morris JC; Holtzman DM; Ashton NJ; Blennow K; Stomrud E; Bateman RJ; Hansson O
    JAMA Neurol; 2024 Sep; 81(9):947-957. PubMed ID: 39068669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
    Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
    JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
    Ashton NJ; Puig-Pijoan A; Milà-Alomà M; Fernández-Lebrero A; García-Escobar G; González-Ortiz F; Kac PR; Brum WS; Benedet AL; Lantero-Rodriguez J; Day TA; Vanbrabant J; Stoops E; Vanmechelen E; Triana-Baltzer G; Moughadam S; Kolb H; Ortiz-Romero P; Karikari TK; Minguillon C; Hernández Sánchez JJ; Navalpotro-Gómez I; Grau-Rivera O; María Manero R; Puente-Periz V; de la Torre R; Roquer J; Dage JL; Zetterberg H; Blennow K; Suárez-Calvet M
    Alzheimers Dement; 2023 May; 19(5):1913-1924. PubMed ID: 36370462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
    Bali D; Hansson O; Janelidze S
    Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
    Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
    JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay.
    Dyer AH; Dolphin H; O'Connor A; Morrison L; Sedgwick G; Young C; Killeen E; Gallagher C; McFeely A; Connolly E; Davey N; Claffey P; Doyle P; Lyons S; Gaffney C; Ennis R; McHale C; Joseph J; Knight G; Kelly E; O'Farrelly C; Fallon A; O'Dowd S; Bourke NM; Kennelly SP
    Alzheimers Res Ther; 2024 Aug; 16(1):186. PubMed ID: 39160628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD
    Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.